Lancashire and South Cumbria
Formulary
Formulary
11 Eye
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
11-08-02 Subfoveal choroidal neovascularisation
| Aflibercept Eylea® |
|
Formulary
|
Solution for intravitreal injection pre-filled syringe 40mg/mL |
 MHRA: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw NICE TA: Aflibercept for treating diabetic macular oedema NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion NICE TA486: Aflibercept for treating choroidal neovascularisation |
|
| Brolucizumab Beovu® |
|
Formulary
|
19.8mg/0.165ml solution for injection pre-filled syringes |
|
MHRA: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals NICE TA672: Brolucizumab for treating wet age-related macular degeneration NICE TA820: Brolucizumab for treating diabetic macular oedema |
|
|
| Faricimab Vabysmo® |
|
Formulary
|
Solution for injection 120 mg/mL |
|
NICE TA799: Faricimab for treating diabetic macular oedema NICE TA800: Faricimab for treating wet age-related macular degeneration |
|
|
| Ranibizumab |
|
Formulary
|
Solution for intravitreal injection 10mg/mL
|
|
NICE TA274: Ranibizumab for treating diabetic macular oedema NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal) |
|
|
For NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)Links
- Corneal superficial injury (CKS)
- Does the dose of intravenous fluorescein sodium need to be adjusted in renal impairment or renal replacement therapy?
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update April 2016: Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw
- MHRA Drug Safety update Jan 2022: Brolucizumab (Beovu): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
- MHRA: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
- MHRA: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA 68: Photodynamic therapy for age related macular degeneration
- NICE TA: Aflibercept for treating diabetic macular oedema
- NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
- NICE TA274: Ranibizumab for treating diabetic macular oedema
- NICE TA274:Ranibizumab for treating diabetic macular oedema - updated 26/10/2023
- NICE TA346: Aflibercept for treating diabetic macular oedema
- NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE TA486: Aflibercept for treating choroidal neovascularisation
- NICE TA486: Aflibercept for treating choroidal neovascularisation
- NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)
- NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)
- NICE TA672: Brolucizumab for treating wet age-related macular degeneration
- NICE TA672: Brolucizumab for treating wet age-related macular degeneration
- NICE TA799: Faricimab for treating diabetic macular oedema
- NICE TA799: Faricimab for treating diabetic macular oedema
- NICE TA800: Faricimab for treating wet age-related macular degeneration
- NICE TA800: Faricimab for treating wet age-related macular degeneration
- NICE TA820: Brolucizumab for treating diabetic macular oedema
- NICE TA820: Brolucizumab for treating diabetic macular oedema
- Pulsion brand SPC (may require password)